NICE guidance on the use of carmustine wafers in high grade gliomas: a national study on variation in practice
Background. Multidisciplinary team (MDT) working in oncology aims to improve outcomes for patients with cancer. One role is to ensure the implementation of best practice and National Institute for Health and Clinical Excellence (NICE) guidance. In this study, we have assessed the role of MDT in impl...
Main Authors: | Price, Stephen J., Whittle, Ian R., Ashkan, Keyoumars, Grundy, Paul, Cruickshank, Garth |
---|---|
Format: | Online |
Language: | English |
Published: |
Informa Healthcare
2012
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432583/ |
Similar Items
-
Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis
by: Chowdhary, Sajeel A., et al.
Published: (2015) -
The Combination of Carmustine Wafers and Fotemustine in Recurrent Glioblastoma Patients: A Monoinstitutional Experience
by: Lombardi, Giuseppe, et al.
Published: (2014) -
Safety and efficacy of carmustine (BCNU) wafers for metastatic brain tumors
by: Ene, Chibawanye I., et al.
Published: (2016) -
Polifeprosan 20, 3.85% carmustine slow-release wafer in malignant glioma: evidence for role in era of standard adjuvant temozolomide
by: Kleinberg, Lawrence
Published: (2012) -
Polifeprosan 20, 3.85% carmustine slow release wafer in malignant glioma: patient selection and perspectives on a low-burden therapy
by: Kleinberg, Lawrence
Published: (2016)